{
  "docId": "019dd923-5ca1-7489-b639-45501f4b359b",
  "docSlug": "158df8627a0b9aca",
  "documentTitle": "Opioid Conflicts Majority Staff Report",
  "authorId": "McKinsey",
  "authorName": "U.S. House Committee on Oversight and Reform",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 27,
  "pageCount": 53,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "appendix_disclosure",
  "function": "appendix",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "This appears to be a page from a formal report or legal document, containing narrative text and extensive footnotes.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/27",
  "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.78,
        "x": 0.11,
        "y": 0.658
      },
      "kind": "disclaimer",
      "text": "127 MCK-HCOR-0355686 to MCK-HCOR-0355698 (McKinsey FDA Engagement List). 128 F.D.A. Nominee Deflects Criticism About Ties to Drugmakers at Hearing... 129 FDA Approves Drugs Faster Than Ever But Relies on Weaker Evidence... 130 MCK-HCOR-0351350, Page 6...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e11cec8c-2d79-4e52-a47f-cf165140ed83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.11,
        "y": 0.155
      },
      "kind": "paragraph",
      "text": "On November 16, 2017, McKinsey entered into a contract with FDA's Office of New Drugs to modernize CDER's New Drugs Regulatory Program, an award valued at $2,669,213.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2423a2cf-633f-46c5-b5d0-e0b6f2694454",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.78,
        "x": 0.11,
        "y": 0.411
      },
      "kind": "paragraph",
      "text": "Mr. Smith began serving as one of the lead McKinsey partners on the FDA New Drugs contract on December 6, 2017. The FDA contract listed him as the primary McKinsey consultant and Engagement Director. Just two days earlier, Mr. Smith had started another engagement at Purdue, called Project Scottsdale...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8c409c4-6a80-44fe-b517-88a41856540b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.78,
        "x": 0.11,
        "y": 0.273
      },
      "kind": "paragraph",
      "text": "FDA's Office of New Drugs oversees investigational studies during the drug development process and assesses the safety and effectiveness of new drugs. McKinsey's 2017 contract with FDA stated that the office needed “a strategic thought partner”...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3875cde-7115-484e-848c-cc2e84fd2d0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.54,
        "x": 0.23,
        "y": 0.115
      },
      "kind": "title",
      "text": "iv. FDA Office of New Drugs Contract (2017-2018)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95e48a5d-6ad1-441b-b489-2628d781ffa0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 6,
      "beatId": "ca9c3ab4-903c-4ff0-b53d-42335d2ce596",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents extensive evidence of McKinsey's conflicts of interest, including consultant overlaps and contract details.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 53,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033",
      "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 40,
      "from": 24,
      "name": "Voice Of Customer",
      "slug": "51-voice-of-customer",
      "bestFor": "Product strategy, customer experience, market research",
      "matchId": "308c22ef-34f3-45b8-b50d-c273c6edeb88",
      "evidence": "The document presents the concerns of regulatory bodies through examples of McKinsey's actions and lack of disclosure.",
      "position": 1,
      "objective": "What are the concerns of regulatory bodies regarding McKinsey's conflicts of interest?",
      "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
      "confidence": 0.6,
      "description": "Let customer quotes and feedback drive the narrative and validate the insight"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}